Abstract
Purpose Chemosaturation percutaneous hepatic perfusion (CS-PHP) allows selective intrahepatic
delivery of high dose cytotoxic melphalan in patients with curatively untreatable
liver tumors while limiting systemic toxicity through hemofiltration of the hepatic
venous blood. Aim of this study was to investigate the response to therapy, survival
and safety of the CS-PHP procedure in patients with liver-dominant metastatic uveal
melanoma (UM).
Materials and Methods Overall response rate (ORR) and disease control rate (DCR) were assessed according
to Response Evaluation Criteria In Solid Tumors (RECIST1.1). Median overall survival
(mOS), median progression-free survival (mPFS) and hepatic progression-free survival
(mhPFS) were analyzed using Kaplan-Meier estimation. Adverse events were evaluated
with Common Terminology Criteria for Adverse Events (CTCAE) v5.
Results Overall, 30 patients were treated with 70 CS-PHP in a salvage setting from October
2014 to January 2019. In total, ORR and DCR were 42.3 % and 80.8 %, respectively.
Overall, mOS was 12 (95 % confidence interval (CI) 7–15) months, and both, mPFS and
mhPFS were 6 months, respectively (95 % CI 4–10; 95 % CI 4–13). Adverse events (AE)
most frequently included significant but transient hematologic toxicities (87 % of
grade 3/4 thrombocytopenia), less frequent AEs were hepatic injury extending to liver
failure (3 %), cardiovascular events including one case of ischemic stroke (3 %).
Conclusion Salvage treatment with CS-PHP is effective in selected patients with UM. The interventional
procedure is safe. Serious hepatic and cardiovascular events, although rare, require
careful patient selection and should be closely monitored.
Key Points:
-
CS-PHP is safe for selected patients with liver-dominant metastatic uveal melanoma.
-
CS-PHP resulted in hepatic disease control in 80 % of patients.
-
Hematologic events following CS-PHP are common but manageable.
Citation Format
Key words
angiography - chemotherapy - interventional procedures - percutaneous - interventional
oncology
